T1	Participants 57 141	patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
T2	Participants 309 353	patients with poor left-ventricular function
T3	Participants 692 722	patients at high risk of death
T4	Participants 1295 1364	1486 patients (743 in the amiodarone group, 743 in the placebo group)
